½ÃÀ庸°í¼­
»óǰÄÚµå
1269696

¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : ¿ëµµº°, ¿¬·É´ëº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° ºÐ¼®(2022-2029³â)

Global Cerebral Oximetry Monitoring Market Size study & Forecast, by Application, by Age Group, by End Use and Regional Analysis, 2022-2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀåÀº 2021³â ¾à 1¾ï 8,904¸¸ ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, 2022-2029³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 7.20% ÀÌ»óÀÇ °ß°íÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÉÇ÷°ü ¼ö¼úÀÇ ¼ö¼ú ÀüÈÄ¿¡´Â ±ÙÀû¿Ü¼± ºÐ±¤¹ý(NIRS)¿¡ ±â¹ÝÇÑ ³ú³» »ê¼ÒÆ÷È­µµ ÃøÁ¤ÀÌ ´õ ÀÚÁÖ »ç¿ëµË´Ï´Ù. ÀÌ´Â ÀüµÎ¿± ÇÇÁúÀÇ ±¹¼ÒÀûÀÎ »ê¼Ò Æ÷È­µµ¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû ±â¼úÀÔ´Ï´Ù. ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀåÀº ³ëÀÎ Àα¸ Áõ°¡, ½ÉÇ÷°ü Áúȯ ¹× ½Å°æ Áúȯ°ú °°Àº Áúȯ Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ´Ù¸¸, ³ú³» »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µÀÇ ³ôÀº ºñ¿ëÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹Ì±¹ Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(Centers for Disease Control and Prevention)¿¡ µû¸£¸é, ¼­À¯·´½Ä »ýȰ½À°ü, °úµµÇÑ À½ÁÖ, Èí¿¬, ¿îµ¿ ºÎÁ·À¸·Î ÀÎÇØ 2020³â¿¡´Â 697,000¸íÀÇ ¹Ì±¹ÀÎÀÌ °ü»óµ¿¸ÆÁúȯ(CAD)¿¡ °É¸± °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.(CDC), CAD ȯÀÚ Áõ°¡¿¡ µû¶ó ¾ÈÀüÇÑ CAD ¼ö¼úÀ» À§ÇØ ³ú³» »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ÀåÄ¡ÀÇ Çʿ伺ÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, °í·ÉÈ­ ¹× ºñ¸¸ Àα¸´Â ¸¸¼º Áúȯ¿¡ °É¸®±â ½±´Ù. ¼¼°èÀºÇà ±×·ìÀº 2050³â±îÁö ¼¼°è ³ëÀÎ Àα¸°¡ 15¾ï ¸íÀ¸·Î 2020³â ÇöÀç 7¾ï 2,700¸¸ ¸í¿¡¼­ ´Ã¾î³¯ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¶ÇÇÑ, Á¦Ç° °³¹ßÀÇ ¹ßÀü°ú ´Ù¾çÇÑ ±ÔÁ¦ ±â°üÀÇ ½ÂÀÎÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀå¿¡ À¯¸®ÇÏ°Ô ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¸¶½Ã¸ð´Â 2020³â 8¿ù¿¡ FDA·ÎºÎÅÍ 'O3 Regional Oximetry' ±â¼úÀ» »ç¿ëÇÏ¿© ½Åü Á¶Á÷ÀÇ »ê¼Ò Æ÷È­µµ¿Í ¼ºÀÎ ³úÀÇ ¿Á½ÃÇì¸ð±Û·Îºó, Çì¸ð±Û·Îºó ¹× µ¥¿Á½ÃÇì¸ð±Û·Îºó »çÀÌÀÇ º¯µ¿À» ¸ð´ÏÅ͸µÇÏ´Â FDA ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù.

¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì ¹× ±âŸ Áö¿ªÀÔ´Ï´Ù. ºÏ¹Ì´Â ºê·£µå Á¦Ç°ÀÇ ¿ìÀ§¿Í ÀÌ Áö¿ªÀÇ Áúº´ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¸ÅÃâ·Î ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ³ë·É Àα¸ ¹× ´ë»ó Àα¸ Áõ°¡, Á¦Ç° °³¹ßÀ» À§ÇÑ Á¦ÈÞ Áõ°¡, ÁÖ¿ä ±â¾÷ÀÇ Áö¿ª È®Àå, Á¤ºÎ ±â°ü ½ÃÀå ÁøÀÔ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â µ¿¾È ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ Á¤ÀÇÇϰí ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡¿¡¼­ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇöȲ
  • ¼¼°è¡¤ºÎ¹®º° ½ÃÀå ÃßÁ¤¡¤¿¹Ãø, 2019³â-2029³â
    • ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå, Áö¿ªº°, 2019-2029³â
    • ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå, ¿ëµµº°, 2019-2029³â
    • ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå, ¿¬·ÉÃþº°, 2019-2029³â
    • ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2019-2029³â
  • ÁÖ¿ä µ¿Çâ
  • Á¶»ç ¹æ¹ý
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç

Á¦2Àå ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • Á¶»ç ´ë»ó ¹üÀ§
    • »ê¾÷ ÁøÈ­
  • Á¶»ç ´ë»ó³âµµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå ¿ªÇÐ

  • ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ¿µÇ⠺м®(2019-2029³â)
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • ½ÃÀå ±âȸ

Á¦4Àå ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five Forces ¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù(2019-2029³â)
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ¾÷°è °ü°èÀÚÀÇ Àü¸Á
  • ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð

Á¦5Àå ¸®½ºÅ© Æò°¡ : COVID-19ÀÇ ¿µÇâ

  • COVID-19°¡ ¾÷°è¿¡°Ô ÁÖ´Â ÀüüÀûÀÎ ¿µÇâ¿¡ °üÇÑ Æò°¡
  • COVID-19 ÀÌÀü°ú COVID-19 ÀÌÈÄÀÇ ½ÃÀå ½Ã³ª¸®¿À

Á¦6Àå ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå : ¿ëµµº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå : ¿ëµµº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå ÃßÁ¤¡¤¿¹Ãø(¿ëµµº°) 2019-2029
  • ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ½ÉÀå¿Ü°ú
    • Ç÷°ü¿Ü°ú
    • ±âŸ

Á¦7Àå ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå : ¿¬·ÉÃþº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå : ¿¬·ÉÃþº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå ¿¬·ÉÃþº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
  • ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ¼Ò¾Æ°ú
    • ¼ºÀÎ

Á¦8Àå ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
  • ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • º´¿ø ¹× Áø·á¼Ò
    • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
    • ±âŸ

Á¦9Àå ¼¼°èÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå : Áö¿ªº° ºÐ¼®

  • ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå, Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø, 2019³â-2029³â
      • ¿¬·ÉÃþº° ÃßÁ¤¡¤¿¹Ãø, 2019³â-2029³â
      • ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø, 2019³â-2029³â
    • ij³ª´Ù
  • À¯·´ÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå °³¿ä
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå °³¿ä
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ³ú »ê¼ÒÆ÷È­µµ ÃøÁ¤ ¸ð´ÏÅ͸µ ½ÃÀå °³¿ä
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • ¼¼°è ±âŸ Áö¿ª

Á¦10Àå °æÀï Á¤º¸

  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Masimo
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • Medtronic
    • Edwards Lifesciences Corporation
    • Nonin Medical Inc
    • ISS, Inc.
    • Hamamatsu Photonics K.K.
    • Mespere LifeSciences Inc
    • GE Healthcare
    • Terumo Cardiovascular Systems Corporation
    • Ornim Medical

Á¦11Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • ¹ë¸®µ¥À̼Ç
    • ÃâÆÇ
  • Á¶»ç Ư¡
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
LSH 23.05.24

Global Cerebral Oximetry Monitoring Market is valued at approximately USD 189.04 million in 2021 and is anticipated to grow with a healthy growth rate of more than 7.20% over the forecast period 2022-2029. During the perioperative period of cardiovascular surgeries, cerebral oximetry based on near-infrared spectroscopy (NIRS) is employed more frequently. It is a non-invasive technique that can keep track of the frontal cortex's local oxygen saturation. The Cerebral Oximetry Monitoring Market is expanding because of factors such as the growing geriatric population and an increasing number of diseases such as cardiovascular and neurological disorders. However, the high cost of cerebral oximetry monitoring devices may halt market growth.

According to the centres for disease control and prevention, 697,000 Americans are expected to have coronary artery disease (CAD) in 2020 as a result of adopting a western lifestyle, heavy drinking, heavy smoking, and inactivity (CDC). As CAD cases increase, it is expected that the need for cerebral oximetry monitoring devices to perform safe CAD surgery would rise. Aging and obese populations are also more likely to develop chronic diseases. The World Bank Group projects that by 2050, there will be 1.5 billion older people in the world, up from the current 727 million estimate of 2020.In addition, advancements in product development and rising approval by various regulatory bodies are creating lucrative growth in the market. For instance, Masimo got FDA approval in August 2020 to use its "O3 Regional Oximetry" technology to monitor the oxygenation saturation of somatic tissues and the variations between oxyhemoglobin, hemoglobin, and deoxyhemoglobin in adult brains.

The key regions considered for the Global Cerebral Oximetry Monitoring Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government organizations in the market space.

Major market player included in this report are:

  • Masimo
  • Medtronic
  • Edwards Lifesciences Corporation
  • Nonin Medical Inc
  • ISS, Inc.
  • Hamamatsu Photonics K.K.
  • Mespere LifeSciences Inc
  • GE Healthcare
  • Terumo Cardiovascular Systems Corporation
  • Ornim Medical

Recent Developments in the Market:

  • In December 2021, The FDA has granted 510(k) approval for the Medtronic PLC INVOS 7100 cerebral/somatic oximetry device for use in pediatric patients. The INVOS system enables pediatric clinicians caring for neonates, premature infants, children, and other patients to make timely decisions on ventilation, hemodynamic management, and resuscitation.
  • In August 2020, The FDA approved the use of O3 Regional Oximetry to measure the oxygenation saturation of somatic tissues in all patient groups as well as the relative changes in hemoglobin, oxyhemoglobin, and deoxyhemoglobin in adult brains.

Global Cerebral Oximetry Monitoring Market Report Scope:

  • Historical Data 2019-2020-2021
  • Base Year for Estimation 2021
  • Forecast period 2022-2029
  • Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered Application, Age, End Use, Region
  • Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Application:

  • Cardiac Surgery
  • Vascular Surgery
  • Others

By Age:

  • Pediatric
  • Adult

By End Use:

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
    • 1.2.1. Cerebral Oximetry Monitoring Market, by Region, 2019-2029 (USD Million)
    • 1.2.2. Cerebral Oximetry Monitoring Market, by Application, 2019-2029 (USD Million)
    • 1.2.3. Cerebral Oximetry Monitoring Market, by Age Group, 2019-2029 (USD Million)
    • 1.2.4. Cerebral Oximetry Monitoring Market, by End Use, 2019-2029 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Cerebral Oximetry Monitoring Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Cerebral Oximetry Monitoring Market Dynamics

  • 3.1. Cerebral Oximetry Monitoring Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing Geriatric Population
      • 3.1.1.2. Increasing number of diseases such as cardiovascular and neurological disorders
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of cerebral oximetry monitoring device
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Advancements in product development
      • 3.1.3.2. Rising approval by various regulatory bodies

Chapter 4. Global Cerebral Oximetry Monitoring Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Cerebral Oximetry Monitoring Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Cerebral Oximetry Monitoring Market by Application, Performance - Potential Analysis
  • 6.3. Global Cerebral Oximetry Monitoring Market Estimates & Forecasts by Application 2019-2029 (USD Million)
  • 6.4. Cerebral Oximetry Monitoring Market, Sub Segment Analysis
    • 6.4.1. Cardiac Surgery
    • 6.4.2. Vascular Surgery
    • 6.4.3. Others

Chapter 7. Global Cerebral Oximetry Monitoring Market, by Age Group

  • 7.1. Market Snapshot
  • 7.2. Global Cerebral Oximetry Monitoring Market by Age Group, Performance - Potential Analysis
  • 7.3. Global Cerebral Oximetry Monitoring Market Estimates & Forecasts by Age Group 2019-2029 (USD Million)
  • 7.4. Cerebral Oximetry Monitoring Market, Sub Segment Analysis
    • 7.4.1. Pediatric
    • 7.4.2. Adult

Chapter 8. Global Cerebral Oximetry Monitoring Market, by End Use

  • 8.1. Market Snapshot
  • 8.2. Global Cerebral Oximetry Monitoring Market by End Use, Performance - Potential Analysis
  • 8.3. Global Cerebral Oximetry Monitoring Market Estimates & Forecasts by End Use 2019-2029 (USD Million)
  • 8.4. Cerebral Oximetry Monitoring Market, Sub Segment Analysis
    • 8.4.1. Hospitals & Clinics
    • 8.4.2. Ambulatory Surgical Centers
    • 8.4.3. Others

Chapter 9. Global Cerebral Oximetry Monitoring Market, Regional Analysis

  • 9.1. Cerebral Oximetry Monitoring Market, Regional Market Snapshot
  • 9.2. North America Cerebral Oximetry Monitoring Market
    • 9.2.1. U.S. Cerebral Oximetry Monitoring Market
      • 9.2.1.1. Application breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Age Group breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. End Use breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Cerebral Oximetry Monitoring Market
  • 9.3. Europe Cerebral Oximetry Monitoring Market Snapshot
    • 9.3.1. U.K. Cerebral Oximetry Monitoring Market
    • 9.3.2. Germany Cerebral Oximetry Monitoring Market
    • 9.3.3. France Cerebral Oximetry Monitoring Market
    • 9.3.4. Spain Cerebral Oximetry Monitoring Market
    • 9.3.5. Italy Cerebral Oximetry Monitoring Market
    • 9.3.6. Rest of Europe Cerebral Oximetry Monitoring Market
  • 9.4. Asia-Pacific Cerebral Oximetry Monitoring Market Snapshot
    • 9.4.1. China Cerebral Oximetry Monitoring Market
    • 9.4.2. India Cerebral Oximetry Monitoring Market
    • 9.4.3. Japan Cerebral Oximetry Monitoring Market
    • 9.4.4. Australia Cerebral Oximetry Monitoring Market
    • 9.4.5. South Korea Cerebral Oximetry Monitoring Market
    • 9.4.6. Rest of Asia Pacific Cerebral Oximetry Monitoring Market
  • 9.5. Latin America Cerebral Oximetry Monitoring Market Snapshot
    • 9.5.1. Brazil Cerebral Oximetry Monitoring Market
    • 9.5.2. Mexico Cerebral Oximetry Monitoring Market
    • 9.5.3. Rest of Latin America Cerebral Oximetry Monitoring Market
  • 9.6. Rest of The World Cerebral Oximetry Monitoring Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Masimo
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Medtronic
    • 10.2.3. Edwards Lifesciences Corporation
    • 10.2.4. Nonin Medical Inc
    • 10.2.5. ISS, Inc.
    • 10.2.6. Hamamatsu Photonics K.K.
    • 10.2.7. Mespere LifeSciences Inc
    • 10.2.8. GE Healthcare
    • 10.2.9. Terumo Cardiovascular Systems Corporation
    • 10.2.10. Ornim Medical

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦